In short
CART45RA-NKG2D Cells are being studied in clinical trials as a potential treatment for refractory/relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults, as well as for advanced sarcoma. This innovative cell therapy uses genetically modified T cells to target cancer cells more effectively. The trials aim to evaluate the safety, feasibility, and efficacy of this promising approach in patients who have not responded to conventional treatments.
At a glance
- Treatment
- CART45RA-NKG2D Cells
- Cancer Types
- Refractory/relapsed acute lymphoblastic leukemia (ALL), Advanced sarcoma
- Patient Age
- Children, adolescents, and young adults (up to 30 or 40 years old)
- Administration
- Intravenous infusion, potentially combined with local administration
- Trial Phase
- Phase I
- Primary Objectives
- Safety, feasibility, dose-limiting toxicity, maximum tolerated dose
- Secondary Objectives
- Efficacy, cell persistence, cytokine profiles, biomarker analysis
- Key Eligibility
- Refractory/relapsed disease, no standard treatment options available
What is CART45RA-NKG2D?
CART45RA-NKG2D is an innovative cell therapy being studied for the treatment of certain types of cancer. It belongs to a class of treatments called CAR-T cell therapy, which stands for Chimeric Antigen Receptor T-cell therapy. This treatment involves modifying a patient's own immune cells (T cells) or donor cells to better recognize and fight cancer cells.
Target Conditions
CART45RA-NKG2D is being investigated for two main types of cancer:
- Refractory/relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults
- Advanced sarcoma in children, adolescents, and young adults
These conditions are typically difficult to treat with standard therapies, especially when they have come back (relapsed) or are not responding to treatment (refractory).
How It Works
CART45RA-NKG2D cells are designed to target specific proteins on cancer cells. For ALL, they target proteins called CD19 and CD22 on B-cell leukemia cells, or NKG2D ligands on T-cell leukemia cells. For sarcoma, they target NKG2D ligands on tumor cells. These modified T cells are equipped with a special receptor (CAR) that helps them recognize and attack cancer cells more effectively.
Clinical Trials
CART45RA-NKG2D is currently being studied in Phase I clinical trials. These trials aim to:
- Determine the safety and feasibility of the treatment
- Find the right dose that can be tolerated by patients
- See how well the treatment works against the cancer
- Understand how long the modified T cells stay in the body
- Study the effects on the immune system and cancer cells
Eligibility Criteria
To participate in these trials, patients generally need to meet certain criteria, including:
- Age: Usually under 30 or 40 years old at diagnosis or relapse
- Having cancer that has not responded to or has come back after standard treatments
- Good overall health status
- Adequate organ function
- For sarcoma trials, having tumors that express certain proteins (NKG2D ligands)
Administration
CART45RA-NKG2D cells are given as an intravenous infusion, which means they are delivered directly into the bloodstream. The treatment may be given in multiple doses, depending on the specific trial and the patient's response.
Potential Benefits
While it's important to remember that CART45RA-NKG2D is still in early stages of research, potential benefits being studied include:
- Ability to target cancer cells that have become resistant to other treatments
- Potential for long-lasting effects as the modified T cells can persist in the body
- Possibility of achieving remission in patients who have run out of other treatment options
Safety Considerations
As with any experimental treatment, there are potential risks and side effects. The clinical trials are carefully monitoring for:
- Cytokine release syndrome (CRS): A condition where the immune system becomes overly activated
- Infections
- Effects on normal blood cells
- Any unexpected side effects
Patients in the trials are closely monitored and receive supportive care as needed to manage any side effects.